617 related articles for article (PubMed ID: 23487174)
1. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
Powell DR; Smith M; Greer J; Harris A; Zhao S; DaCosta C; Mseeh F; Shadoan MK; Sands A; Zambrowicz B; Ding ZM
J Pharmacol Exp Ther; 2013 May; 345(2):250-9. PubMed ID: 23487174
[TBL] [Abstract][Full Text] [Related]
2. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
3. Effect of LX4211 on glucose homeostasis and body composition in preclinical models.
Powell DR; DaCosta CM; Smith M; Doree D; Harris A; Buhring L; Heydorn W; Nouraldeen A; Xiong W; Yalamanchili P; Mseeh F; Wilson A; Shadoan M; Zambrowicz B; Ding ZM
J Pharmacol Exp Ther; 2014 Aug; 350(2):232-42. PubMed ID: 24849925
[TBL] [Abstract][Full Text] [Related]
4. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
[TBL] [Abstract][Full Text] [Related]
5. Improved glycemic control in mice lacking Sglt1 and Sglt2.
Powell DR; DaCosta CM; Gay J; Ding ZM; Smith M; Greer J; Doree D; Jeter-Jones S; Mseeh F; Rodriguez LA; Harris A; Buhring L; Platt KA; Vogel P; Brommage R; Shadoan MK; Sands AT; Zambrowicz B
Am J Physiol Endocrinol Metab; 2013 Jan; 304(2):E117-30. PubMed ID: 23149623
[TBL] [Abstract][Full Text] [Related]
6. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
Zambrowicz B; Freiman J; Brown PM; Frazier KS; Turnage A; Bronner J; Ruff D; Shadoan M; Banks P; Mseeh F; Rawlins DB; Goodwin NC; Mabon R; Harrison BA; Wilson A; Sands A; Powell DR
Clin Pharmacol Ther; 2012 Aug; 92(2):158-69. PubMed ID: 22739142
[TBL] [Abstract][Full Text] [Related]
7. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
[TBL] [Abstract][Full Text] [Related]
8. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
Martinussen C; Veedfald S; Dirksen C; Bojsen-Møller KN; Svane MS; Wewer Albrechtsen NJ; van Hall G; Kristiansen VB; Fenger M; Holst JJ; Madsbad S
Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E956-E964. PubMed ID: 32182123
[TBL] [Abstract][Full Text] [Related]
9. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice.
Moriya R; Shirakura T; Ito J; Mashiko S; Seo T
Am J Physiol Endocrinol Metab; 2009 Dec; 297(6):E1358-65. PubMed ID: 19808907
[TBL] [Abstract][Full Text] [Related]
10. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release.
Dobbins RL; Greenway FL; Chen L; Liu Y; Breed SL; Andrews SM; Wald JA; Walker A; Smith CD
Am J Physiol Gastrointest Liver Physiol; 2015 Jun; 308(11):G946-54. PubMed ID: 25767259
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet.
Hira T; Koga T; Sasaki K; Hara H
Biochem Biophys Res Commun; 2017 Oct; 492(2):161-165. PubMed ID: 28803984
[TBL] [Abstract][Full Text] [Related]
12. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
13. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
14. Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Hikida K; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Minami M; Shiotani M
J Pharmacol Sci; 2016 Dec; 132(4):255-261. PubMed ID: 27889414
[TBL] [Abstract][Full Text] [Related]
15. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion.
Zambrowicz B; Lapuerta P; Strumph P; Banks P; Wilson A; Ogbaa I; Sands A; Powell D
Clin Ther; 2015 Jan; 37(1):71-82.e12. PubMed ID: 25529979
[TBL] [Abstract][Full Text] [Related]
16. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
Song P; Onishi A; Koepsell H; Vallon V
Expert Opin Ther Targets; 2016 Sep; 20(9):1109-25. PubMed ID: 26998950
[TBL] [Abstract][Full Text] [Related]
17. SGL5213, a novel and potent intestinal SGLT1 inhibitor, suppresses intestinal glucose absorption and enhances plasma GLP-1 and GLP-2 secretion in rats.
Io F; Gunji E; Koretsune H; Kato K; Sugisaki-Kitano M; Okumura-Kitajima L; Kimura K; Uchida S; Yamamoto K
Eur J Pharmacol; 2019 Jun; 853():136-144. PubMed ID: 30878385
[TBL] [Abstract][Full Text] [Related]
18. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2011 Feb; 96(2):447-53. PubMed ID: 21047927
[TBL] [Abstract][Full Text] [Related]
19. Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study.
Posch MG; Walther N; Ferrannini E; Powell DR; Banks P; Wason S; Dahmen R
Diabetes Care; 2022 Sep; 45(9):2118-2126. PubMed ID: 35817022
[TBL] [Abstract][Full Text] [Related]
20. Circulating concentrations of glucagon-like peptide 1, glucose-dependent insulinotropic peptide, peptide YY, and insulin in client-owned lean, overweight, and diabetic cats.
McMillan CJ; Zapata RC; Chelikani PK; Snead EC; Cosford K
Domest Anim Endocrinol; 2016 Jan; 54():85-94. PubMed ID: 26609567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
